White Paper - Faster Time to Market: Approaches to Biometrics for Emerging Biopharma Companies
Register here to download the full white paper
Emerging Biopharma Companies (EBPs) are dominating the global clinical trial landscape, with clinical trial starts growing nearly 200% from 2011-2021. As EBPs often face resource constraints, they increasingly rely on CROs for clinical development, fueling significant growth in the CRO services market.
The rise in trial complexity, use of real-world data, and stricter regulatory requirements are driving the need for advanced biometrics solutions to ensure high-quality, standardised data for successful regulatory submissions.
- EBPs play an increasingly important role in biopharma R&D: EBPs now represent 95% of all companies with active pipelines and 72% of all drugs in the development pipeline.
- The volume and complexity of data from clinical trials are sharply increasing: Data volume per trial has increased three-fold over recent year
- EBPs have a range of options for managing biometrics: Outsourcing biometrics to external CROs minimises the risk of data errors/issues and maximises efficiency
- Key factors when choosing a CRO: EBPs prefer to work with specialist biometrics services providers, hoping to build strong, long-term partnerships.
Together with Frost & Sullivan and Bioforum, Cytel has compiled this white paper to guide you in choosing the right CRO.
Download your copy by filling in the form to the right.